BioNexus Launches New Corporate Website with Expanded Business and Investor Resources
Key Highlights
- ➤BioNexus (BGLC) launches redesigned corporate website with expanded investor resources
- ➤Website consolidates MRNA Scientific, Chemrex, healthcare investments and technology relationships
- ➤Dedicated pages detail blood-based genomic screening and VitaGuard™ residual disease platform
- ➤Expanded investor section provides SEC filings, reports, governance materials and shareholder information
Expert Statements
Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp.
“Investors and potential partners should be able to understand what BioNexus operates today, what we are developing and how our technology relationships fit together. The new website brings that information into one place and gives visitors a clearer route to our public reporting and the people responsible for advancing the business.”
KUALA LUMPUR, Malaysia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”) today announced the launch of its redesigned corporate website at www.bionexusgenelab.com, providing investors, business partners and other visitors with a more comprehensive view of the Company’s operations and development initiatives.
The website brings together information about MRNA Scientific’s RNA screening business, Chemrex’s industrial chemical and composite-materials business, and BioNexus’ recent healthcare investments and technology relationships. Dedicated technology pages explain blood-based genomic screening and the VitaGuard™ molecular residual disease platform, including their respective applications and development context.
Get started
Create a free account to read the full story.